Acne Medication Market by Therapeutic Class (Retinoids, Antibiotics, Salicylic Acid, Benzoyl Peroxide, and Others), Formulation (Topical Medications and Oral Medications), Type (Prescription Medicines and Over-The-Counter Medicines), Acne Type (Non-Inflammatory Acne and Inflammatory Acne), and Distribution Channel (Retail Stores, Pharmacies & Drug Stores, and E-Commerce): Global Opportunity Analysis and Industry Forecast, 2019-2027
- ALL4079359
- 278 Pages
- September 2020
- Pharmaceuticals
Acne is a common skin disorder that is mainly caused by excessive production of sebum. In this disorder, there is an outbreak of lesions, which are known as pimples. Acne usually begins at puberty and the condition may worsen during adolescence. It can be treated by acne medications depending upon severity. Acne treatment includes reduction of sebum production, removal of dead skin cells, and killing of bacteria with the help of oral medications and drugs. Acne medications are either applied directly, which are present in formulations or taken in the form of oral pills. These medications work by reducing inflammation and oil production. They also fight with bacteria finally preventing scarring. Common acne medications include retinoids, antibiotics, isotretinoin, and benzoyl peroxide.
Growth of the global acne medication market is driven by rise in prevalence of acne diseases, which is the major factor that contributes toward growth of the acne medication market. Moreover, other factors that fuel the market growth include unhealthy urban lifestyle and presence of robust acne medications in pipeline. However, side-effects associated with the use of acne medications and presence of alternative treatment impede the market growth. Conversely, development of effective medications with lesser side effects and high market potential in untapped emerging economies are expected to provide lucrative growth opportunities for the market growth.
The global acne medication market is segmented into therapeutic class, formulation, type, acne type, distribution channel, and region. By therapeutic class, the market is divided into retinoids, antibiotics, salicylic acid, benzoyl peroxide, and others. The retinoids segment is further classified into topical retinoid & combination retinoid and oral retinoid (isotretinoin). Moreover, the antibiotics segment is further sub-segmented into topical antibiotics & combination antibiotics and oral antibiotics.
On the basis of formulation, the market is bifurcated into topical medication and oral medication. By type, it is divided into prescription medicine and over-the-counter (OTC) medicine. By acne type, it is fragmented into non-inflammatory and inflammatory acne. By distribution channel, it is classified into retail store, pharmacy & drug store, and e-commerce. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
KEY BENEFITS FOR STAKEHOLDERS
This report entails a detailed quantitative analysis of the current market trends from 2019 to 2027 to identify prevailing opportunities along with strategic assessment of the global acne medication market.
Market size and estimations are based on a comprehensive analysis of end users, developments, and services in the industry.
An in-depth analysis based on region assists to understand the regional market and facilitates strategic business planning.
Developmental strategies adopted by the key market players are enlisted to understand the competitive scenario of the market.
KEY MARKET SEGMENTS
By Therapeutic Class
• Retinoid
o Topical Retinoid & Combination Retinoid
o Oral Retinoid (Isotretinoin)
• Antibiotic
o Topical Antibiotic & Combination Antibiotics
o Oral Antibiotics
• Salicylic Acid
• Benzoyl Peroxide
• Others
By Formulation
• Topical Medication
• Oral Medication
By Type
• Prescription Medicine
• Over-the-counter (OTC) Medicine
By Acne Type
• Inflammatory Acne
• Non-inflammatory Acne
By Distribution Channel
• Retail Store
• Pharmacy & Drug Store
• E-Commerce
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o France
o UK
o Italy
o Spain
o Rest of Europe
• Asia-Pacific
o Japan
o China
o India
o Australia
o South Korea
o Rest of Asia-Pacific
• LAMEA
o Brazil
o Saudi Arabia
o South Africa
o Rest of LAMEA
KEY MARKET PLAYERS
• Almirall SA.
• Bausch Health Companies Inc.
• GlaxoSmithKline Plc (GSK)
• Johnson & Johnson
• Galderma S.A
• Mayne Pharma Group Limited
• Mylan N.V.
• Pfizer Inc.
• Sun Pharmaceutical Industries Limited
• Teva Pharmaceutical Industries Ltd.
1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments
1.4.List of key players profiled in the report
1.5.Research methodology
1.5.1.Secondary research
1.5.2.Primary research
1.5.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.CXO perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.2.2.Top winning strategies
3.3.Top player positioning, 2019
3.4.Market dynamics
3.4.1.Drivers
3.4.1.1.Increase in prevalence of acne diseases
3.4.1.2.Unhealthy urban lifestyle
3.4.1.3.Rise in focus on skin care products
3.4.2.Restraints
3.4.2.1.Side effects associated with acne medications
3.4.2.2.Presence of alternatives for acne treatment
3.4.3.Opportunities
3.4.3.1.Opportunities in emerging economies
3.4.3.2.Development of therapeutics with lesser side effects
3.4.4.Impact analyses
3.5.Clinical trials
3.6.Patent analysis (2011–2020)
3.6.1.Patent analysis, by year
3.7.Impact of COVID-19 on Acne Medication Market
CHAPTER 4:ACNE MEDICATION MARKET, BY THERAPEUTIC CLASS
4.1.Overview
4.1.1.Market size and forecast
4.2.Retinoid
4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast, by type
4.2.2.1.Topical & combination retinoids
4.2.2.1.1.Market size and forecast, by region
4.2.2.2.Oral retinoid (Isotretinoin)
4.2.2.2.1.Market size and forecast, by region
4.2.3.Market size and forecast, by region
4.2.4.Market analysis, by country
4.3.Antibiotics
4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast, by type
4.3.2.1.Topical & combination antibiotics
4.3.2.1.1.Market size and forecast, by region
4.3.2.2.Oral antibiotics
4.3.2.2.1.Market size and forecast, by region
4.3.3.Market size and forecast, by region
4.3.4.Market analysis, by country
4.4.Salicylic acid
4.4.1.Key market trends, growth factors, and opportunities
4.4.2.Market size and forecast, by region
4.4.3.Market analysis, by country
4.5.Benzoyl Peroxide
4.5.1.Key market trends, growth factors, and opportunities
4.5.2.Market size and forecast, by region
4.5.3.Market analysis, by country
4.6.Other medications
4.6.1.Key market trends, growth factors, and opportunities
4.6.2.Market size and forecast, by region
4.6.3.Market analysis, by country
CHAPTER 5:ACNE MEDICATION MARKET, BY FORMULATION
5.1.Overview
5.1.1.Market size and forecast
5.2.Topical medications
5.2.1.Market size and forecast, by region
5.2.2.Market analysis, by country
5.3.Oral medications
5.3.1.Market size and forecast, by region
5.3.2.Market analysis, by country
CHAPTER 6:ACNE MEDICATION MARKET, BY TYPE
6.1.Overview
6.1.1.Market size and forecast
6.2.Prescription medicines
6.2.1.Market size and forecast, by region
6.2.2.Market analysis, by country
6.3.Over-the-counter medicines
6.3.1.Market size and forecast, by region
6.3.2.Market analysis, by country
CHAPTER 7:ACNE MEDICATION MARKET, BY ACNE TYPE
7.1.Overview
7.1.1.Market size and forecast
7.2.Non-inflammatory acne
7.2.1.Market size and forecast, by region
7.2.2.Market analysis, by country
7.3.Inflammatory acne
7.3.1.Market size and forecast, by region
7.3.2.Market analysis, by country
CHAPTER 8:ACNE MEDICATION MARKET, BY DISTRIBUTION CHANNEL
8.1.Overview
8.1.1.Market size and forecast
8.2.Retail store
8.2.1.Market size and forecast, by region
8.2.2.Market analysis, by country
8.3.Pharmacy & drug store
8.3.1.Market size and forecast, by region
8.3.2.Market analysis, by country
8.4.E-Commerce
8.4.1.Market size and forecast, by region
8.4.2.Market analysis, by country
CHAPTER 9:ACNE MEDICATION MARKET, BY REGION
9.1.Overview
9.1.1.Market size and forecast
9.2.North America
9.2.1.Key market trends, growth factors, and opportunities
9.2.2.North America acne medication market, by country
9.2.2.1.U.S.
9.2.2.1.1.Market size and forecast, by therapeutic class
9.2.2.1.2.Market size and forecast, by type
9.2.2.1.3.Market size and forecast, by acne type
9.2.2.1.4.Market size and forecast, by distribution channel
9.2.2.2.Canada
9.2.2.2.1.Market size and forecast, by therapeutic class
9.2.2.2.2.Market size and forecast, by type
9.2.2.2.3.Market size and forecast, by acne type
9.2.2.2.4.Market size and forecast, by distribution channel
9.2.2.3.Mexico
9.2.2.3.1.Market size and forecast, by therapeutic class
9.2.2.3.2.Market size and forecast, by type
9.2.2.3.3.Market size and forecast, by acne type
9.2.2.3.4.Market size and forecast, by distribution channel
9.2.3.North America market size and forecast, by therapeutic class
9.2.4.North America market size and forecast, by formulation
9.2.5.North America market size and forecast, by type
9.2.6.North America market size and forecast, by acne type
9.2.7.North America market size and forecast, by distribution channel
9.3.Europe
9.3.1.Key market trends, growth factors, and opportunities
9.3.2.Europe market size and forecast, by country
9.3.2.1.Germany
9.3.2.1.1.Market size and forecast, by therapeutic class
9.3.2.1.2.Market size and forecast, by type
9.3.2.1.3.Market size and forecast, by acne type
9.3.2.1.4.Market size and forecast, by distribution channel
9.3.2.2.France
9.3.2.2.1.Market size and forecast, by therapeutic class
9.3.2.2.2.Market size and forecast, by type
9.3.2.2.3.Market size and forecast, by acne type
9.3.2.2.4.Market size and forecast, by distribution channel
9.3.2.3.UK
9.3.2.3.1.Market size and forecast, by therapeutic class
9.3.2.3.2.Market size and forecast, by type
9.3.2.3.3.Market size and forecast, by acne type
9.3.2.3.4.Market size and forecast, by distribution channel
9.3.2.4.Italy
9.3.2.4.1.Market size and forecast, by therapeutic class
9.3.2.4.2.Market size and forecast, by type
9.3.2.4.3.Market size and forecast, by acne type
9.3.2.4.4.Market size and forecast, by distribution channel
9.3.2.5.Spain
9.3.2.5.1.Market size and forecast, by therapeutic class
9.3.2.5.2.Market size and forecast, by type
9.3.2.5.3.Market size and forecast, by acne type
9.3.2.5.4.Market size and forecast, by distribution channel
9.3.2.6.Rest of Europe
9.3.2.6.1.Market size and forecast, by therapeutic class
9.3.2.6.2.Market size and forecast, by type
9.3.2.6.3.Market size and forecast, by acne type
9.3.2.6.4.Market size and forecast, by distribution channel
9.3.3.Europe market size and forecast, by therapeutic class
9.3.4.Europe market size and forecast, by formulation
9.3.5.Europe market size and forecast, by type
9.3.6.Europe market size and forecast, by acne type
9.3.7.Europe market size and forecast, by distribution channel
9.4.Asia-Pacific
9.4.1.Key market trends, growth factors, and opportunities
9.4.2.Asia-Pacific market size and forecast, by country
9.4.2.1.Japan
9.4.2.1.1.Market size and forecast, by therapeutic class
9.4.2.1.2.Market size and forecast, by type
9.4.2.1.3.Market size and forecast, by acne type
9.4.2.1.4.Market size and forecast, by distribution channel
9.4.2.2.China
9.4.2.2.1.Market size and forecast, by therapeutic class
9.4.2.2.2.Market size and forecast, by type
9.4.2.2.3.Market size and forecast, by acne type
9.4.2.2.4.Market size and forecast, by distribution channel
9.4.2.3.India
9.4.2.3.1.Market size and forecast, by therapeutic class
9.4.2.3.2.Market size and forecast, by type
9.4.2.3.3.Market size and forecast, by acne type
9.4.2.3.4.Market size and forecast, by distribution channel
9.4.2.4.Australia
9.4.2.4.1.Market size and forecast, by therapeutic class
9.4.2.4.2.Market size and forecast, by type
9.4.2.4.3.Market size and forecast, by acne type
9.4.2.4.4.Market size and forecast, by distribution channel
9.4.2.5.South Korea
9.4.2.5.1.Market size and forecast, by therapeutic class
9.4.2.5.2.Market size and forecast, by type
9.4.2.5.3.Market size and forecast, by acne type
9.4.2.5.4.Market size and forecast, by distribution channel
9.4.2.6.Rest of Asia-Pacific
9.4.2.6.1.Market size and forecast, by therapeutic class
9.4.2.6.2.Market size and forecast, by type
9.4.2.6.3.Market size and forecast, by acne type
9.4.2.6.4.Market size and forecast, by distribution channel
9.4.3.Asia-Pacific market size and forecast, by therapeutic class
9.4.4.Asia-Pacific market size and forecast, by formulation
9.4.5.Asia-Pacific market size and forecast, by type
9.4.6.Asia-Pacific market size and forecast, by acne type
9.4.7.Asia-Pacific market size and forecast, by distribution channel
9.5.LAMEA
9.5.1.Key market trends, growth factors, and opportunities
9.5.2.LAMEA market size and forecast, by country
9.5.2.1.Brazil
9.5.2.1.1.Market size and forecast, by therapeutic class
9.5.2.1.2.Market size and forecast, by type
9.5.2.1.3.Market size and forecast, by acne type
9.5.2.1.4.Market size and forecast, by distribution channel
9.5.2.2.Saudi Arabia
9.5.2.2.1.Market size and forecast, by therapeutic class
9.5.2.2.2.Market size and forecast, by type
9.5.2.2.3.Market size and forecast, by acne type
9.5.2.2.4.Market size and forecast, by distribution channel
9.5.2.3.South Africa
9.5.2.3.1.Market size and forecast, by therapeutic class
9.5.2.3.2.Market size and forecast, by type
9.5.2.3.3.Market size and forecast, by acne type
9.5.2.3.4.Market size and forecast, by distribution channel
9.5.2.4.Rest of LAMEA
9.5.2.4.1.Market size and forecast, by therapeutic class
9.5.2.4.2.Market size and forecast, by type
9.5.2.4.3.Market size and forecast, by acne type
9.5.2.4.4.Market size and forecast, by distribution channel
9.5.3.LAMEA market size and forecast, by therapeutic class
9.5.4.LAMEA market size and forecast, by formulation
9.5.5.LAMEA market size and forecast, by type
9.5.6.LAMEA market size and forecast, by acne type
9.5.7.LAMEA market size and forecast, by distribution channel
CHAPTER 10:COMPANY PROFILES
10.1.ALMIRALL SA
10.1.1.Company overview
10.1.2.Company snapshot
10.1.3.Operating business segments
10.1.4.Product portfolio
10.1.5.Business performance
10.1.6.Key strategic moves and developments
10.2.BAUSCH HEALTH COMPANIES INC.
10.2.1.Company overview
10.2.2.Company snapshot
10.2.3.Operating business segments
10.2.4.Product portfolio
10.2.5.Business performance
10.2.6.Key strategic moves and developments
10.3.GLAXOSMITHKLINE PLC (GSK)
10.3.1.Company overview
10.3.2.Company snapshot
10.3.3.Operating business segments
10.3.4.Product portfolio
10.3.5.Business performance.
10.4.JOHNSON & JOHNSON
10.4.1.Company overview
10.4.2.Company snapshot
10.4.3.Operating business segments
10.4.4.Product portfolio
10.4.5.Business performance
10.5.GALDERMA S.A.
10.5.1.Company overview
10.5.2.Company snapshot
10.5.3.Operating business segments
10.5.4.Product portfolio
10.5.5.Key strategic moves and developments
10.6.MAYNE PHARMA GROUP LIMITED
10.6.1.Company overview
10.6.2.Company snapshot
10.6.3.Operating business segments
10.6.4.Product portfolio
10.6.5.Business performance
10.6.6.Key strategic moves and developments
10.7.MYLAN N.V.
10.7.1.Company overview
10.7.2.Company snapshot
10.7.3.Operating business segments
10.7.4.Product portfolio
10.7.5.Business performance
10.8.SUN PHARMACEUTICAL INDUSTRIES LIMITED
10.8.1.Company overview
10.8.2.Company snapshot
10.8.3.Operating business segments
10.8.4.Product portfolio
10.8.5.Business performance
10.8.6.Key strategic moves and developments
10.9.PFIZER INC.
10.9.1.Company overview
10.9.2.Company snapshot
10.9.3.Operating business segments
10.9.4.Product portfolio
10.9.5.Business performance
10.10.TEVA PHARMACEUTICAL INDUSTRIES LTD.
10.10.1.Company overview
10.10.2.Company snapshot
10.10.3.Operating business segments
10.10.4.Product portfolio
10.10.5.Business performance
10.10.6.Key strategic moves and developments
TABLE 01.CLINICAL TRIALS ONGOING IN THE WORLD
TABLE 02.ACNE MEDICATION MARKET, BY THERAPEUTIC CLASS, 2019–2027 ($MILLION)
TABLE 03.RETINOID ACNE MEDICATION MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 04.TOPICAL RETINOID & COMBINATION RETINOID MARKET, BY REGION, 2019–2027 ($MILLION)
TABLE 05.ORAL RETINOID (ISOTRETINOIN) MARKET, BY REGION, 2019–2027 ($MILLION)
TABLE 06.ACNE MEDICATION MARKET FOR RETINOID, BY REGION, 2019–2027 ($MILLION)
TABLE 07.ANTIBIOTICS ACNE MEDICATION MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 08.TOPICAL ANTIBIOTICS & COMBINATION ANTIBIOTICS MARKET, BY REGION, 2019–2027 ($MILLION)
TABLE 09.ORAL ANTIBIOTICS MARKET, BY REGION, 2019–2027 ($MILLION)
TABLE 10.ANTIBIOTICS MARKET, BY REGION, 2019–2027 ($MILLION)
TABLE 11.ACNE MEDICATION MARKET FOR SALICYLIC ACID, BY REGION, 2019–2027 ($MILLION)
TABLE 12.BENZOYL PEROXIDE MARKET, BY REGION, 2019–2027 ($MILLION)
TABLE 13.ACNE MEDICATION MARKET FOR OTHERS, BY REGION, 2019–2027 ($MILLION)
TABLE 14.ACNE MEDICATION MARKET, BY FORMULATION, 2019–2027 ($MILLION)
TABLE 15.ACNE MEDICATIONS MARKET FOR TOPICAL MEDICATION MARKET, BY REGION, 2019–2027 ($MILLION)
TABLE 16.GLOBAL ACNE MEDICATIONS MARKET, FOR ORAL MEDICATION, BY REGION, 2019–2027 ($MILLION)
TABLE 17.GLOBAL ACNE MEDICATION MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 18.ACNE MEDICATION MARKET FOR PRESCRIPTION MEDICINE, BY REGION, 2019–2027 ($MILLION)
TABLE 19.ACNE MEDICATION MARKET FOR OVER-THE-COUNTER, BY REGION, 2019–2027 ($MILLION)
TABLE 20.ACNE MEDICATION MARKET, BY ACNE TYPE, 2019–2027 ($MILLION)
TABLE 21.ACNE MEDICATION MARKET FOR NON-INFLAMMATORY ACNE, BY REGION, 2019–2027 ($MILLION)
TABLE 22.ACNE MEDICATION MARKET FOR INFLAMMTORY ACNE, BY REGION, 2019–2027 ($MILLION)
TABLE 23.ACNE MEDICATION MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 24.GLOBAL ACNE MEDICATION MARKET FOR RETAIL STORE, BY REGION, 2019–2027 ($MILLION)
TABLE 25.ACNE MEDICATION MARKET FOR PHARMACY & DRUG STORE, BY REGION, 2019–2027 ($MILLION)
TABLE 26.ACNE MEDICATION MARKET FOR E-COMMERCE, BY REGION, 2019–2027 ($MILLION)
TABLE 27.ACNE MEDICATION MARKET, BY REGION, 2019–2027 ($MILLION)
TABLE 28.NORTH AMERICA ACNE MEDICATION MARKET, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 29.U.S. ACNE MEDICATION MARKET, BY THERAPEUTIC CLASS, 2019–2027 ($MILLION)
TABLE 30.U.S. ACNE MEDICATION MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 31.U.S. ACNE MEDICATION MARKET, BY ACNE TYPE, 2019–2027 ($MILLION)
TABLE 32.U.S. ACNE MEDICATION MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 33.CANADA ACNE MEDICATION MARKET, BY THERAPEUTIC CLASS, 2019–2027 ($MILLION)
TABLE 34.CANADA ACNE MEDICATION MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 35.CANADA ACNE MEDICATION MARKET, BY ACNE TYPE, 2019–2027 ($MILLION)
TABLE 36.CANADA ACNE MEDICATION MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 37.MEXICO ACNE MEDICATION MARKET, BY THERAPEUTIC CLASS, 2019–2027 ($MILLION)
TABLE 38.MEXICO ACNE MEDICATION MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 39.MEXICO ACNE MEDICATION MARKET, BY ACNE TYPE, 2019–2027 ($MILLION)
TABLE 40.MEXICO ACNE MEDICATION MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 41.NORTH AMERICA ACNE MEDICATION MARKET, BY THERAPEUTIC CLASS, 2019–2027 ($MILLION)
TABLE 42.NORTH AMERICA ACNE MEDICATION MARKET, BY FORMULATION, 2019–2027 ($MILLION)
TABLE 43.NORTH AMERICA ACNE MEDICATION MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 44.NORTH AMERICA ACNE MEDICATION MARKET, BY ACNE TYPE, 2019–2027 ($MILLION)
TABLE 45.NORTH AMERICA ACNE MEDICATION MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 46.EUROPE ACNE MEDICATION MARKET, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 47.GERMANY ACNE MEDICATION MARKET, BY THERAPEUTIC CLASS, 2019–2027 ($MILLION)
TABLE 48.GERMANY ACNE MEDICATION MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 49.GERMANY ACNE MEDICATION MARKET, BY ACNE TYPE, 2019–2027 ($MILLION)
TABLE 50.GERMANY ACNE MEDICATION MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 51.FRANCE ACNE MEDICATION MARKET, BY THERAPEUTIC CLASS, 2019–2027 ($MILLION)
TABLE 52.FRANCE ACNE MEDICATION MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 53.FRANCE ACNE MEDICATION MARKET, BY ACNE TYPE, 2019–2027 ($MILLION)
TABLE 54.FRANCE ACNE MEDICATION MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 55.UK ACNE MEDICATION MARKET, BY THERAPEUTIC CLASS, 2019–2027 ($MILLION)
TABLE 56.UK ACNE MEDICATION MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 57.UK ACNE MEDICATION MARKET, BY ACNE TYPE, 2019–2027 ($MILLION)
TABLE 58.UK ACNE MEDICATION MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 59.ITALY ACNE MEDICATION MARKET, BY THERAPEUTIC CLASS, 2019–2027 ($MILLION)
TABLE 60.ITALY ACNE MEDICATION MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 61.ITALY ACNE MEDICATION MARKET, BY ACNE TYPE, 2019–2027 ($MILLION)
TABLE 62.ITALY ACNE MEDICATION MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 63.SPAIN ACNE MEDICATION MARKET, BY THERAPEUTIC CLASS, 2019–2027 ($MILLION)
TABLE 64.SPAIN ACNE MEDICATION MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 65.SPAIN ACNE MEDICATION MARKET, BY ACNE TYPE, 2019–2027 ($MILLION)
TABLE 66.SPAIN ACNE MEDICATION MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 67.REST OF EUROPE ACNE MEDICATION MARKET, BY THERAPEUTIC CLASS, 2019–2027 ($MILLION)
TABLE 68.REST OF EUROPE ACNE MEDICATION MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 69.REST OF EUROPE ACNE MEDICATION MARKET, BY ACNE TYPE, 2019–2027 ($MILLION)
TABLE 70.REST OF EUROPE ACNE MEDICATION MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 71.EUROPE ACNE MEDICATION MARKET, BY THERAPEUTIC CLASS, 2019–2027 ($MILLION)
TABLE 72.EUROPE ACNE MEDICATION MARKET, BY FORMULATION, 2019–2027 ($MILLION)
TABLE 73.EUROPE ACNE MEDICATION MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 74.EUROPE ACNE MEDICATION MARKET, BY ACNE TYPE, 2019–2027 ($MILLION)
TABLE 75.EUROPE ACNE MEDICATION MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 76.ASIA-PACIFIC ACNE MEDICATION MARKET, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 77.JAPAN ACNE MEDICATION MARKET, BY THERAPEUTIC CLASS, 2019–2027 ($MILLION)
TABLE 78.JAPAN ACNE MEDICATION MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 79.JAPAN ACNE MEDICATION MARKET, BY ACNE TYPE, 2019–2027 ($MILLION)
TABLE 80.JAPAN ACNE MEDICATION MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 81.CHINA ACNE MEDICATION MARKET, BY THERAPEUTIC CLASS, 2019–2027 ($MILLION)
TABLE 82.CHINA ACNE MEDICATION MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 83.CHINA ACNE MEDICATION MARKET, BY ACNE TYPE, 2019–2027 ($MILLION)
TABLE 84.CHINA ACNE MEDICATION MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 85.INDIA ACNE MEDICATION MARKET, BY THERAPEUTIC CLASS, 2019–2027 ($MILLION)
TABLE 86.INDIA ACNE MEDICATION MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 87.INDIA ACNE MEDICATION MARKET, BY ACNE TYPE, 2019–2027 ($MILLION)
TABLE 88.INDIA ACNE MEDICATION MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 89.AUSTRALIA ACNE MEDICATION MARKET, BY THERAPEUTIC CLASS, 2019–2027 ($MILLION)
TABLE 90.AUSTRALIA ACNE MEDICATION MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 91.AUSTRALIA ACNE MEDICATION MARKET, BY ACNE TYPE, 2019–2027 ($MILLION)
TABLE 92.AUSTRALIA ACNE MEDICATION MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 93.SOUTH KOREA ACNE MEDICATION MARKET, BY THERAPEUTIC CLASS, 2019–2027 ($MILLION)
TABLE 94.SOUTH KOREA ACNE MEDICATION MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 95.SOUTH KOREA ACNE MEDICATION MARKET, BY ACNE TYPE, 2019–2027 ($MILLION)
TABLE 96.SOUTH KOREA ACNE MEDICATION MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 97.REST OF ASIA-PACIFIC ACNE MEDICATION MARKET, BY THERAPEUTIC CLASS, 2019–2027 ($MILLION)
TABLE 98.REST OF ASIA-PACIFIC ACNE MEDICATION MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 99.REST OF ASIA-PACIFIC ACNE MEDICATION MARKET, BY ACNE TYPE, 2019–2027 ($MILLION)
TABLE 100.REST OF ASIA-PACIFIC ACNE MEDICATION MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 101.ASIA-PACIFIC ACNE MEDICATION MARKET, BY THERAPEUTIC CLASS, 2019–2027 ($MILLION)
TABLE 102.ASIA-PACIFIC ACNE MEDICATION MARKET, BY FORMULATION, 2019–2027 ($MILLION)
TABLE 103.ASIA-PACIFIC ACNE MEDICATION MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 104.ASIA-PACIFIC ACNE MEDICATION MARKET, BY ACNE TYPE, 2019–2027 ($MILLION)
TABLE 105.ASIA-PACIFIC ACNE MEDICATION MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 106.LAMEA ACNE MEDICATION MARKET, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 107.BRAZIL ACNE MEDICATION MARKET, BY THERAPEUTIC CLASS, 2019–2027 ($MILLION)
TABLE 108.BRAZIL ACNE MEDICATION MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 109.BRAZIL ACNE MEDICATION MARKET, BY ACNE TYPE, 2019–2027 ($MILLION)
TABLE 110.BRAZIL ACNE MEDICATION MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 111.SAUDI ARABIA ACNE MEDICATION MARKET, BY THERAPEUTIC CLASS, 2019–2027 ($MILLION)
TABLE 112.SAUDI ARABIA ACNE MEDICATION MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 113.SAUDI ARABIA ACNE MEDICATION MARKET, BY ACNE TYPE, 2019–2027 ($MILLION)
TABLE 114.SAUDI ARABIA ACNE MEDICATION MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 115.SOUTH AFRICA ACNE MEDICATION MARKET, BY THERAPEUTIC CLASS, 2019–2027 ($MILLION)
TABLE 116.SOUTH AFRICA ACNE MEDICATION MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 117.SOUTH AFRICA ACNE MEDICATION MARKET, BY ACNE TYPE, 2019–2027 ($MILLION)
TABLE 118.SOUTH AFRICA ACNE MEDICATION MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 119.REST OF LAMEA ACNE MEDICATION MARKET, BY THERAPEUTIC CLASS, 2019–2027 ($MILLION)
TABLE 120.REST OF LAMEA ACNE MEDICATION MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 121.REST OF LAMEA ACNE MEDICATION MARKET, BY ACNE TYPE, 2019–2027 ($MILLION)
TABLE 122.REST OF LAMEA ACNE MEDICATION MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 123.LAMEA ACNE MEDICATION MARKET, BY THERAPEUTIC CLASS, 2019–2027 ($MILLION)
TABLE 124.LAMEA ACNE MEDICATION MARKET, BY FORMULATION, 2019–2027 ($MILLION)
TABLE 125.LAMEA ACNE MEDICATION MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 126.LAMEA ACNE MEDICATION MARKET, BY ACNE TYPE, 2019–2027 ($MILLION)
TABLE 127.LAMEA ACNE MEDICATION MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 128.ALMIRALL : COMPANY SNAPSHOT
TABLE 129.ALMIRALL: OPERATING SEGMENT
TABLE 130.ALMIRAL : PRODUCT PORTFOLIO
TABLE 131.ALMIRALL: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 132.BAUSCH: COMPANY SNAPSHOT
TABLE 133.BAUSCH: OPERATING SEGMENTS
TABLE 134.BAUSCH: PRODUCT PORTFOLIO
TABLE 135.GSK: COMPANY SNAPSHOT
TABLE 136.GSK: OPERATING SEGMENTS
TABLE 137.GSK: PRODUCT PORTFOLIO
TABLE 138.J&J: COMPANY SNAPSHOT
TABLE 139.J&J: OPERATING BUSINESS SEGMENTS
TABLE 140.J&J: PRODUCT PORTFOLIO
TABLE 141.GALDERMA : COMPANY SNAPSHOT
TABLE 142.GALDERMA : OPERATING SEGMENTS
TABLE 143.GALDERMA : PRODUCT PORTFOLIO
TABLE 144.MAYNE PHARMA: COMPANY SNAPSHOT
TABLE 145.MAYNE PHARMA: OPERATING SEGMENTS
TABLE 146.MAYNE PHARMA: PRODUCT PORTFOLIO
TABLE 147.MYLAN: COMPANY SNAPSHOT
TABLE 148.MYLAN: OPERATING BUSINESS SEGMENTS
TABLE 149.MYLAN: PRODUCT PORTFOLIO
TABLE 150.SUN PHARMA: COMPANY SNAPSHOT
TABLE 151.SUN PHARMA: OPERATING SEGMENTS
TABLE 152.SUN PHARMA: PRODUCT PORTFOLIO
TABLE 153.PFIZER: COMPANY SNAPSHOT
TABLE 154.PFIZER: OPERATING SEGMENT
TABLE 155.PFIZER: PRODUCT PORTFOLIO
TABLE 156.TEVA: COMPANY SNAPSHOT
TABLE 157.TEVA: OPERATING SEGMENTS
TABLE 158.TEVA: PRODUCT PORTFOLIO
Similar Reports
Proteins that are designed and engineered in the laboratory for pharmaceutical interventions to treat different diseases are known as protein therapeutics. The global protein therapeutics market accounted for $140,109 million in 2016, and is anticipated to rea...
- Publish Date: November 14, 2017
- $5370
Umbilical cord blood bank is storage facility that collects cord blood after the childbirth from placenta. Cord blood is rich source of stem cell used in treatment of different chronic diseases. Private and public cord blood banks are the two major types of banks that are prevalent in th...
- Publish Date: July 20, 2017
- $5370
The pharmaceutical agents that are administered to treat, diagnose, and prevent life-threatening diseases (rare diseases) are known as orphan drugs. The global orphan drugs market accounted for $106 billion in 2015, and is anticipated to reach $169 billio...
- Publish Date: April 24, 2017
- $5370
